Details of the Drug

General Information of Drug (ID: DMYRBO1)

Drug Name
Umbralisib
Synonyms RP5264; TGR-1202
Indication
Disease Entry ICD 11 Status REF
Follicular lymphoma 2A80 Approved [1]
Marginal zone lymphoma 2A85.0 Approved [1]
Diffuse large B-cell lymphoma 2A81 Phase 2/3 [2]
Chronic lymphocytic leukaemia 2A82.0 Phase 2 [3]
Non-hodgkin lymphoma 2B33.5 Phase 2 [3]
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 571.5
Logarithm of the Partition Coefficient (xlogp) 5.8
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 10
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 4 h [4]
Clearance
The clearance of drug is 15.5 L/h [5]
Elimination
During pharmacokinetic studies, about 81% of the umbralisib dose was recovered in feces (17% unchanged) [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 91 hours [5]
Metabolism
The drug is metabolized via the CYP2C9, CYP3A4, and CYP1A2 enzymes [5]
Vd
The volume of distribution (Vd) of drug is 312 L [5]
Chemical Identifiers
Formula
C31H24F3N5O3
IUPAC Name
2-[(1S)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one
Canonical SMILES
C[C@@H](C1=C(C(=O)C2=C(O1)C=CC(=C2)F)C3=CC(=CC=C3)F)N4C5=NC=NC(=C5C(=N4)C6=CC(=C(C=C6)OC(C)C)F)N
InChI
InChI=1S/C31H24F3N5O3/c1-15(2)41-24-9-7-18(12-22(24)34)27-26-30(35)36-14-37-31(26)39(38-27)16(3)29-25(17-5-4-6-19(32)11-17)28(40)21-13-20(33)8-10-23(21)42-29/h4-16H,1-3H3,(H2,35,36,37)/t16-/m0/s1
InChIKey
IUVCFHHAEHNCFT-INIZCTEOSA-N
Cross-matching ID
PubChem CID
72950888
CAS Number
1532533-67-7
DrugBank ID
DB14989
TTD ID
D0O8SJ
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Casein kinase I epsilon (CSNK1E) TTA8PLI KC1E_HUMAN Inhibitor [1]
PI3-kinase delta (PIK3CD) TTGBPJE PK3CD_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Follicular lymphoma
ICD Disease Classification 2A80
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
PI3-kinase delta (PIK3CD) DTT PIK3CD 4.31E-16 -0.37 -0.91
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
2 ClinicalTrials.gov (NCT02793583) Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Burris HA 3rd, Flinn IW, Patel MR, Fenske TS, Deng C, Brander DM, Gutierrez M, Essell JH, Kuhn JG, Miskin HP, Sportelli P, Weiss MS, Vakkalanka S, Savona MR, O'Connor OA: Umbralisib, a novel PI3Kdelta and casein kinase-1epsilon inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncol. 2018 Apr;19(4):486-496. doi: 10.1016/S1470-2045(18)30082-2. Epub 2018 Feb 20.
5 FDA Approved Drug Products: UKONIQ (umbralisib) tablets, for oral use